Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$84.00 USD

84.00
5,514,054

+0.08 (0.10%)

Updated Sep 23, 2024 04:00 PM ET

After-Market: $84.00 0.00 (0.00%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Boston Scientific (BSX) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

Boston Scientific (BSX) closed at $84 in the latest trading session, marking a +0.1% move from the prior day.

TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU

by Zacks Equity Research

Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.

Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Is Boston Scientific (BSX) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market.

Boston Scientific (BSX) Is Up 2.10% in One Week: What You Should Know

by Zacks Equity Research

Does Boston Scientific (BSX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Boston Scientific Corporation (BSX) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles

by Zacks Equity Research

Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.

DGX Stock to Benefit From New Partnership With Sentara Health Plans

by Zacks Equity Research

Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.

MMSI Stock Likely to Gain From Cook Medical's Product Portfolio Buyout

by Zacks Equity Research

Merit Medical expects to solidify its foothold in the underpenetrated global lead management market via the latest asset acquisition.

Here's Why You Should Retain Integer Holdings Stock in Your Portfolio Now

by Zacks Equity Research

ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.

TMO Stock to Gain From Expanded Bioanalytical Services in Sweden

by Zacks Equity Research

Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Reasons to Retain EYE Stock in Your Portfolio for Now

by Zacks Equity Research

The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.

Is Teleflex Stock a Smart Option for Your Portfolio Right Now?

by Zacks Equity Research

TFX instils optimism with its robust performance in the Interventional category and potential in Asia.

MASI Stock Gains as US Court Raises Concern About Politan's Ethics

by Zacks Equity Research

Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept. 19.

Stryker Stock Declines Despite Completion of care.ai Acquisition

by Zacks Equity Research

SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.

Here's Why Boston Scientific (BSX) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?

by Zacks Equity Research

Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.

CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA

by Zacks Equity Research

Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.

Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

Boston Scientific (BSX) closed the most recent trading day at $82.52, moving -1.19% from the previous trading session.

Is Phibro Stock Worth Retaining in Your Portfolio Now?

by Zacks Equity Research

PAHC Animal Health business, supported by the flourishing vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.

Labcorp Stock Gains From Its Latest Acquisition of BioReference Health

by Zacks Equity Research

LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.

Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS

by Zacks Equity Research

MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.

QGEN Stock Likely to Gain From Innovation Amid Competition

by Zacks Equity Research

To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.